PubMed · 2006 · 68 citations · 15 references
MedicineOncologyPharmacologyApoptosisCancer PharmacologyChemotherapyApoptosis In CancerApoptosis PharmacologyApoptosis RegulationCell Cycle PharmacologyCell DeathCytotoxic ChemotherapyApoptosis InductionCancer Cell ApoptosisCell Cycle DynamicsCell Cycle InhibitionCell Cycle InhibitorsChemotherapy-induced ApoptosisInfusion DurationOxaliplatin-based Therapy
BACKGROUND: The effects of oxaliplatin (L-OHP) on cell cycle and apoptosis were examined. MATERIALS AND METHODS: The HT29, MCF7, Hela and A549 cell lines were treated and dual parameter flow cytometry BrdU/PI was then performed to monitor cell cycle modifications. Annexin V-FITC and PI probes were used for the detection of apoptosis. RESULTS: The cells were treated for 3 h followed or not by 24 and 72 h of post-incubation. No changes were observed after 3 h of treatment, while after 24 h of post-incubation, all the cells except A549 were predominantly accumulated in the G2/M-phase; this accumulation was time-dependent. Apoptosis induction was late and moderate and was observed only after 12 h of treatment and 24 h of post-incubation. CONCLUSION: L-OHP induced cell cycle arrest and moderate apoptosis; these two activities were time-dependent. These findings warrant further investigation into the potential antitumour activity of L-OHP in MCF7 and Hela cells and in lengthening the infusion duration in order to achieve the acquired cellular modifications.
15
Olivier Rixe, Waldo Ortuzar, Manuel Álvarez et al. · Biochemical Pharmacology · 1996 · 615 citations
Medicine, Oncology, Pharmacology +15
Cellular and molecular pharmacology of oxaliplatin.
Éric Raymond, Sandrine Faivre, Stephen G. Chaney et al. · PubMed · 2002 · 467 citations
Medicine, Oncology, Pharmacology +17
Joyce T. Reardon, Alexandra Vaisman, Stephen G. Chaney et al. · PubMed · 1999 · 288 citations